MHR (Monocyte-to-HDL Ratio)

The Monocyte-to-HDL Ratio (MHR) is an emerging biomarker that bridges two critical aspects of cardiovascular health — inflammation and lipid metabolism. It is calculated by dividing the number of circulating monocytes, a type of white blood cell involved in immune and inflammatory responses, by the concentration of high-density lipoprotein cholesterol (HDL-C), which exerts anti-inflammatory and antioxidant effects.

This ratio effectively captures the balance between pro-inflammatory activity (monocytes) and anti-inflammatory defense (HDL). When MHR is elevated, it suggests that inflammation is outpacing the body’s ability to regulate it — a dynamic that plays a central role in the development and progression of atherosclerosis and cardiovascular disease (CVD).

Chronic inflammation and lipid imbalance are two sides of the same coin in cardiovascular disease. Monocytes are key players in this process — they adhere to the endothelium, migrate into arterial walls, and transform into macrophages that engulf oxidized LDL cholesterol, forming foam cells, a hallmark of plaque formation. HDL cholesterol helps counter this process by inhibiting monocyte activation, reducing oxidative stress, and facilitating cholesterol efflux from arterial walls.

A higher MHR therefore reflects both heightened inflammatory drive and reduced anti-inflammatory capacity — a powerful dual signal of cardiovascular risk. Studies have shown that individuals with elevated MHR have a significantly greater likelihood of developing coronary artery disease (CAD), even when LDL cholesterol is well controlled. High MHR is also strongly associated with multi-vessel CAD, plaque instability, and long-term mortality in patients with established heart disease.

Beyond predicting coronary disease, MHR serves as a general marker of systemic inflammation, correlating with metabolic disorders such as insulin resistance, metabolic syndrome, and non-alcoholic fatty liver disease. In population studies, higher MHR has been linked with increased incidence of metabolic and cardiovascular diseases, underscoring its value as a metabolic-inflammatory biomarker.

While traditional lipid ratios like the LDL to HDL ratio and the LDL-C to ApoB ratio remain cornerstones of cardiovascular risk assessment, MHR adds a crucial layer by capturing the inflammatory component of heart disease.

The LDL/HDL ratio reflects the balance between atherogenic LDL particles and protective HDL particles — a higher ratio correlates with more severe coronary atherosclerosis and higher rates of cardiac events. The LDL-C/ApoB ratio, on the other hand, acts as a proxy for LDL particle size: a low ratio indicates smaller, denser, and more atherogenic LDL particles, which carry greater cardiovascular risk.

The MHR, however, integrates immune activation into this picture. By combining a marker of inflammation (monocytes) with one of anti-inflammatory protection (HDL), it captures risk that lipid-only markers may miss. This makes MHR a valuable adjunct for patients who have normal LDL levels but ongoing systemic inflammation — a pattern increasingly recognised in metabolic and residual cardiovascular risk.

If your MHR is elevated, it’s a signal to look deeper into your inflammatory and metabolic health. Because MHR reflects both immune activity and lipid balance, it responds strongly to lifestyle and metabolic improvements.

• Focus on anti-inflammatory nutrition: Prioritise a Mediterranean-style diet rich in colourful vegetables, omega-3 fatty acids (from salmon, sardines, flax, or chia), extra-virgin olive oil, and nuts. Minimise refined carbohydrates, seed oils, and ultra-processed foods that promote inflammation.
  

• Exercise regularly: Consistent aerobic and resistance exercise lowers inflammation, boosts HDL levels, and improves overall vascular health.
  

• Support your microbiome: A healthy gut reduces systemic inflammation. Include prebiotic fibre and fermented foods.
  

• Address metabolic drivers: Manage insulin resistance, optimise blood glucose, and maintain a healthy waist circumference — all of which influence monocyte activation.
  

• Clinician oversight: Work with your healthcare provider to monitor MHR alongside markers like hs-CRP, ApoB, and LDL particle size to get a complete picture of your cardiovascular and inflammatory status.
  

By addressing the root causes of inflammation and supporting healthy lipid balance, you can meaningfully improve your MHR — and, in turn, reduce your long-term risk of cardiovascular disease.

1. Liu, M., Liu, X., Wei, Z., et al. (2022). MHR and NHR but not LHR were associated with coronary artery disease in patients with chest pain with controlled LDL-C. Journal of Investigative Medicine, 70(7), 1501–1507. https://doi.org/10.1136/jim-2021-002314
   

2. Chen, J., Wu, K., Cao, W., Shao, J., & Huang, M. (2023). Association between monocyte to high-density lipoprotein cholesterol ratio and multi-vessel coronary artery disease: A cross-sectional study. Lipids in Health and Disease, 22(1), 121. https://doi.org/10.1186/s12944-023-01897-x
   

3. Liu, H. T., Jiang, Z. H., Yang, Z. B., & Quan, X. Q. (2022). Monocyte to high-density lipoprotein ratio predicts long-term clinical outcomes in patients with coronary heart disease: A meta-analysis of 9 studies. Medicine, 101(33), e30109. https://doi.org/10.1097/MD.0000000000030109
   

4. Wang, P., Guo, X., Zhou, Y., et al. (2022). Monocyte-to-high-density lipoprotein ratio and systemic inflammation response index are associated with the risk of metabolic disorders and cardiovascular diseases in the general population. Frontiers in Endocrinology, 13, 944991. https://doi.org/10.3389/fendo.2022.944991
   

5. Sun, T., Chen, M., Shen, H., et al. (2022). Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease. BMC Cardiovascular Disorders, 22(1), 273. https://doi.org/10.1186/s12872-022-02706-6
   

6. Ren, X., & Wang, X. (2023). Association of the LDL-C/HDL-C ratio and major adverse cardiac and cerebrovascular events in coronary heart disease patients undergoing PCI: A cohort study. Current Medical Research and Opinion, 39(9), 1175–1181. https://doi.org/10.1080/03007995.2023.2246889
   

7. Xiao, L., Zhang, K., Wang, F., et al. (2023). The LDL-C/ApoB ratio predicts cardiovascular and all-cause mortality in the general population. Lipids in Health and Disease, 22(1), 104. https://doi.org/10.1186/s12944-023-01869-1
   

8. Drexel, H., Larcher, B., Mader, A., et al. (2021). The LDL-C/ApoB ratio predicts major cardiovascular events in patients with established atherosclerotic cardiovascular disease.Atherosclerosis, 329, 44–49. https://doi.org/10.1016/j.atherosclerosis.2021.05.010